Sorrento Therapeutics IncSorrento Therapeutics Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

Alternative companies in the rating industry group for Sorrento Therapeutics Inc are shownin the table. If you are employed by Sorrento Therapeutics Inc and you wish to licence your ESG rating, please contact us. This analysis of Sorrento Therapeutics Inc uses data points from across the internet as well as from public filings by Sorrento Therapeutics Inc.

Sorrento Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.4; made up of an environmental score of 2.3, social score of 4.0 and governance score of 4.0.

SDG Transparency Score for Sorrento Therapeutics Inc 

3.4

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Sorrento Therapeutics Inc 
2.3

Environmental

4.0

Social

4.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
.........
1617VistaGen Therapeutics Inc
3.5
Medium
1617Yumanity Therapeutics Inc
3.5
Medium
1659Sorrento Therapeutics Inc
3.4
Medium
1659Acceleron Pharma Inc
3.4
Medium
1659Annexin Pharmaceuticals AB (publ)
3.4
Medium
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Sorrento Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc offer flexible work?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose water use targets?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Sorrento Therapeutics Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Sorrento Therapeutics Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Sorrento Therapeutics Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose its waste policy?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose energy use targets?

LockedSign up for free to unlock

Does Sorrento Therapeutics Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Sorrento Therapeutics Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Sorrento Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patients with melanoma; and Karolinska Institutet. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

Sorry!

Failed to process!